Patient death prompts FDA hold on Mersana’s lead cancer ADC

Submitted by admin on July 21, 2018 - 12:14am

Source:

Fierce Biotech

News Tags:

Mersana

XMT-1522

antibody-drug conjugate

patient deaths

clinical trials

Headline:

Patient death prompts FDA hold on Mersana’s lead cancer ADC

snippet:

Another antibody-drug conjugate has been stalled by concerns over safety. The FDA has placed a partial hold on Mersana’s lead candidate XMT-1522 after a patient death in a phase 1 trial, causing its shares to plunge.

Search form

You are here

Patient death prompts FDA hold on Mersana’s lead cancer ADC

Patient death prompts FDA hold on Mersana’s lead cancer ADC